revolution medicines

Approval of the once-daily pill, which extended median survival from 6.7 months to 13 months in late-stage trials, values the company at $46 billion as it targets a previously untreatable protein mutation.

Daraxonrasib cleared 6.5 months early with Phase 3 data showing median 13.2-month survival versus 6.7 months on chemotherapy in second-line metastatic pancreatic cancer.